Poor
Not Aligned
Patient Risk:
Medium
Summary
Most extracted claims concern pricing, copays, savings programs, and patent/competition status, none of which are addressed in the provided FDA-approved Lantus labeling excerpts. Only formulation/delivery details for Lantus Solostar are supported.
Category Scores
Accurate Statements
Lantus is available as an insulin glargine injection.
Supported by 11 DESCRIPTION; 3 DOSAGE FORMS AND STRENGTHS
Lantus Solostar is a prefilled pen designed for single-patient use.
Supported by 11 DESCRIPTION; 3 DOSAGE FORMS AND STRENGTHS
Lantus Solostar delivers 100 units (3 mg) per milliliter.
Supported by 11 DESCRIPTION; 3 DOSAGE FORMS AND STRENGTHS (Each mL contains 100 units of insulin glargine)
Unsupported Statements
The price of Lantus insulin varies depending on factors such as dosage, quantity, and insurance coverage.
Pricing dynamics are not discussed in the provided FDA-approved labeling sections.
Without insurance, a single-box prescription of Lantus Solostar (3 mg/0.3 mL) can range from approximately $200 to over $300.
Dollar price ranges for uninsured purchase are not provided in labeling.
With prescription drug insurance, the out-of-pocket cost for Lantus insulin is typically much lower.
Out-of-pocket cost statements are not provided in labeling.
With prescription drug insurance, copayments for Lantus can range from a few dollars to around $50 per prescription.
Copayment ranges are not provided in labeling.
Lantus Solostar comes in 5 pen-packs.
Pen-pack count is not provided in the provided labeling excerpts.
Lantus Solostar comes in 10 pen-packs.
Pen-pack count is not provided in the provided labeling excerpts.
Sanofi offers a savings program for Lantus that can lower the out-of-pocket cost to as little as $35 per month for eligible patients with commercial insurance.
Manufacturer savings program details and dollar amounts are not included in FDA labeling excerpts.
Savings program eligibility for Lantus typically includes having commercial prescription insurance.
Savings program eligibility criteria are not provided in labeling excerpts.
Savings program eligibility for Lantus typically excludes patients enrolled in government healthcare programs like Medicare or Medicaid.
Savings program exclusion criteria are not provided in labeling excerpts.
Biosimilars to Lantus, such as Semglee (insulin glargine-yfgn), are available.
Availability/comparative market statements about biosimilars are not supported by the provided Lantus labeling excerpts.
Semglee (insulin glargine-yfgn) may offer a lower-cost option.
Comparative cost/value claims about other products are not provided in Lantus labeling excerpts.
Other long-acting insulins include Levemir (insulin detemir).
References to other insulin products are not supported by the provided labeling excerpts.
Other long-acting insulins include Toujeo (insulin glargine U-300).
References to other insulin products are not supported by the provided labeling excerpts.
The primary patents for Lantus have expired in many major markets, paving the way for generic and biosimilar competition.
Patent/exclusivity/market-competition statements are not addressed in the provided labeling excerpts.
U.S. patent exclusivity for Lantus expired around 2015.
Patent/exclusivity status is not addressed in the provided labeling excerpts.
Contradictions
Important Omissions
The response set does not include key FDA label safety content (e.g., boxed warning status, contraindications, warnings/precautions, adverse reactions, dosing/transition instructions, and population-specific guidance). While this omission is not necessarily a direct label contradiction, omitting safety-critical label elements would be material if the response is intended as prescribing information or patient-safety messaging.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The evaluated claims largely relate to pricing/market/access rather than clinical safety. However, omission of safety-critical label elements (depending on intended use/context) could create compliance and patient-safety risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims (pricing, copays, savings programs, biosimilar/other-product and patent/competition assertions) are absent from the provided FDA-approved Lantus labeling.
Suggested Improvement
Limit claims to label-supported product description details (e.g., insulin glargine U-100, Solostar single-patient use, 100 units/mL) and remove or replace unsupported pricing/policy/legal/market-competition statements unless supported by label content included in the provided excerpts.